Home Autoimmune polyglandular syndrome type II with co-manifestation of Addison’s and Graves’ disease in a 15-year-old boy: case report and literature review
Article
Licensed
Unlicensed Requires Authentication

Autoimmune polyglandular syndrome type II with co-manifestation of Addison’s and Graves’ disease in a 15-year-old boy: case report and literature review

  • Lena Schulz and Elke Hammer EMAIL logo
Published/Copyright: March 2, 2020

Abstract

Background

Autoimmune polyglandular syndrome type II (APS II) is defined as the combination of autoimmune adrenal insufficiency and autoimmune thyroid disease (AITD) and/or type I diabetes mellitus (T1DM) in the same patient.

Case presentation

A 15-year-old boy had a history of weight loss, nausea and vomiting, headache, restlessness, and tanned skin. He was diagnosed with Graves’ disease. Two weeks after carbimazol therapy was commenced, he presented with adrenal crises (fever, arterial hypotension, hyponatremia, adrenocorticotropic hormone [ACTH] 1119.6 ng/mL [normal range <60] and low cortisol). He received hydrocortisone and fludrocortisone, and improved quickly. Thyroid-stimulating hormone (TSH) receptor autoantibodies as well as 21-hydroxylase antibodies were elevated.

Conclusions

Although the combination of Graves’ and Addison’s disease is extremely rare, especially in children, it is critical to make the diagnosis. Accelerated metabolic rate increased the risk for adrenal crises in our patient. This case contributes to the spectrum of APS II and its manifestation.


Corresponding author: Dr. Elke Hammer, MD, Catholic Childrens Hospital Wilhelmstift, Department of Paediatrics, Liliencronstrasse 130, 22149 Hamburg, Germany, Phone: +004940673770, Fax: +00494067377380

  1. Author contributions: Both authors have accepted responsibility for the entire content of this submitted manuscript and approved the submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: None declared.

  6. Informed consent: Informed consent was obtained from all individuals included in this case presentation.

References

1. Michels AW, Gottlieb PA. Autoimmune polyglandular syndromes. Nat Rev Endocrinol 2010;6:270–7.10.1038/nrendo.2010.40Search in Google Scholar

2. Majeroni BA, Patel P. Autoimmune polyglandular syndrome type II. Am Fam Physician 2007;75:667–70.Search in Google Scholar

3. Flesch BK, Matheis N, Alt T, Weinstock C, Bux J, et al. HLA class II haplotypes differentiate between the adult autoimmunepolyglandular syndrome types II and III. J Clin Endocrinol Metab 2014;99:E177–82.10.1210/jc.2013-2852Search in Google Scholar

4. Blomhoff A, Lie BA, Myhre AG, Kemp EH, Weetman AP, et al. Polymorphisms in the cytotoxic T lymphocyte antigen-4 gene region confer susceptibility to Addison’s disease. J Clin Endocrinol Metab 2004;89:3474–6.10.1210/jc.2003-031854Search in Google Scholar

5. Schatz DA, Winter WE. Autoimmune polyglandular syndrome. II: clinical syndrome and treatment. Endocrinol Metab Clin North Am 2002;31:339–52.10.1016/S0889-8529(01)00012-3Search in Google Scholar

6. Fichna M, Fichna P, Gryczyńska M, Walkowiak J, Zurawek M, et al. Screening for associated autoimmune disorders in Polish patients with Addison’s disease. Endocrine 2010;37:349–60.10.1007/s12020-010-9312-xSearch in Google Scholar PubMed

7. Zelissen PM, Bast EJ, Croughs RJ. Associated autoimmunity in Addison’s disease. J Autoimmun 1995;8:121–30.10.1006/jaut.1995.0009Search in Google Scholar PubMed

8. Russell GA, Coulter JB, Isherwood DM, Diver MJ, Smith DS. Autoimmune Addison’s disease and thyrotoxic thyroiditis presenting as encephalopathy in twins. Arch Dis Child 1991;66:350–2.10.1136/adc.66.3.350Search in Google Scholar PubMed PubMed Central

9. Newrick PG. Addison’s disease and thyrotoxicosis presenting simultaneously. Postgrad Med J 1984;60:478–9.10.1136/pgmj.60.705.478Search in Google Scholar PubMed PubMed Central

10. Paschkis KE, Rupp JJ. Co-existence of Addison’s disease and thyrotoxicosis. J Clin Endocrinol Metab 1957;17:143–7.10.1210/jcem-17-1-143Search in Google Scholar PubMed

11. Attaye I, van Andel M, Kooter AJ. More, less or both? BMJ Case Rep 2018; 2018. pii: bcr-2017-222355. doi: 10.1136/bcr-2017-222355.10.1136/bcr-2017-222355Search in Google Scholar PubMed PubMed Central

12. Papathanasiou A, Kousta E, Skarpa V, Papachileos P, Petrou V, et al. Growth hormone deficiency in a patient with autoimmune polyendocrinopathy type 2. Hormones (Athens) 2007;6:247–50.Search in Google Scholar

13. Smith RK, Gerrits PM. A rare case of autoimmune polyglandular syndrome type 2 in a child with persistent fatigue. Glob Pediatr Health 2019;6:1–5.10.1177/2333794X19845074Search in Google Scholar PubMed PubMed Central

Received: 2019-10-27
Accepted: 2020-01-06
Published Online: 2020-03-02
Published in Print: 2020-04-28

©2020 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Review
  3. Prevalence of obesity and overweight in Iranian students: a systematic review and meta-analysis
  4. Original Articles
  5. Trends in pediatric obesity management, a survey from the Pediatric Endocrine Society Obesity Committee
  6. Utility of MR proton density fat fraction and its correlation with ultrasonography and biochemical markers in nonalcoholic fatty liver disease in overweight adolescents
  7. Vitamin D status and its relation to insulin resistance in a Mexican pediatric population
  8. Elevated serum uric acid, hyperuricaemia and dietary patterns among adolescents in mainland China
  9. Is there a relationship between the dietary inflammatory index and metabolic syndrome among adolescents?
  10. New insights into the expression of androgen and estrogen receptors of the appendix testis in congenital cryptorchidism
  11. General properties of autoimmune thyroid diseases and associated morbidities
  12. Comparison of leptin levels in neonates born to mothers with high or low gestational weight gain
  13. Percentile values of serum zinc concentration and prevalence of its deficiency in Iranian children and adolescents: the CASPIAN-V study
  14. Nine-year overview of dyslipidemia management in children with heterozygous familial hypercholesterolemia: a university hospital outpatient lipid clinic project in Northwestern Greece
  15. Gesell Developmental Schedules scores and the relevant factors in children with Down syndrome
  16. Letters to the Editor
  17. Society for Pediatric Radiology (SPR) Child Abuse Committee response regarding Miller, Stolfi and Ayoub’s flawed theories about child abuse and metabolic bone disease
  18. Reply of Miller and Ayoub to Brown et al. Letter to the Editor
  19. Case Reports
  20. Identification of two novel variants in GAA underlying infantile-onset Pompe disease in two Pakistani families
  21. Hereditary vitamin D-resistant rickets: a report of four cases with two novel variants in the VDR gene and successful use of intermittent intravenous calcium via a peripheral route
  22. Variant analysis of HPD genes from two families showing elevated tyrosine upon newborn screening by tandem mass spectrometry (MS/MS)
  23. Challenges in the management of an ignored cause of hyperammonemic encephalopathy: pyruvate carboxylase deficiency
  24. Autoimmune polyglandular syndrome type II with co-manifestation of Addison’s and Graves’ disease in a 15-year-old boy: case report and literature review
Downloaded on 2.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/jpem-2019-0506/html?lang=en
Scroll to top button